Skip to main content
Erschienen in: Clinical and Translational Oncology 3/2017

05.08.2016 | Research Article

Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery

verfasst von: J. Arredondo, J. Baixauli, C. Pastor, A. Chopitea, J. J. Sola, I. González, J. A-Cienfuegos, P. Martínez, J. Rodriguez, J. L. Hernández-Lizoain

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Neoadjuvant chemotherapy is being actively tested as an emerging alternative for the treatment of locally advanced colon cancer (LACC) patients, resembling its use in other gastrointestinal tumors. This study assesses the mid-term oncologic outcome of LACC patients treated with oxaliplatin and fluoropyrimidines-based preoperative chemotherapy followed by surgery.

Methods and patients

Patients with radiologically resectable LACC treated with neoadjuvant therapy between 2009 and 2014 were retrospectively analyzed. Radiological, metabolic, and pathological tumor response was assessed. Both postoperative complications, relapse-free survival (RFS), and overall survival (OS) were studied.

Results

Sixty-five LACC patients who received treatment were included. Planned treatment was completed by 93.8 % of patients. All patients underwent surgery without delay. The median time between the start of chemotherapy and surgery was 71 days (65–82). No progressive disease was observed during preoperative treatment. A statistically significant tumor volume reduction of 62.5 % was achieved by CT scan (39.8–79.8) (p < 0.001). It was also observed a median reduction of 40.5 % (24.2–63.7 %) (p < 0.005) of SUVmax (Standard Uptake Value) by PET-CT scan. Complete pathologic response was achieved in 4.6 % of patients. Postoperative complications were observed in 15.4 % of patients, with no cases of mortality. After a median follow-up of 40.1 months, (p 25p 75: 27.3–57.8) 3–5 year actuarial RFS was 88.9–85.6 %, respectively. Five-year actuarial OS was 95.3 %.

Conclusion

Preoperative chemotherapy in LACC patients is safe and able to induce major tumor regression. Survival times are encouraging, and further research seems warranted.
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
2.
Zurück zum Zitat Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.CrossRefPubMed Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.CrossRefPubMed
3.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual (7th ed). New York: Springer; 2010. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual (7th ed). New York: Springer; 2010.
4.
Zurück zum Zitat Kim MJ, Jeong SY, Choi SJ, Ryoo SB, Park JW, Park KJ, et al. Survival paradox between stage IIB/C (T4N0) and stage IIIA (T1-2N1) colon cancer. Ann Surg Oncol. 2015;22:505–12.CrossRefPubMed Kim MJ, Jeong SY, Choi SJ, Ryoo SB, Park JW, Park KJ, et al. Survival paradox between stage IIB/C (T4N0) and stage IIIA (T1-2N1) colon cancer. Ann Surg Oncol. 2015;22:505–12.CrossRefPubMed
5.
Zurück zum Zitat Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11–6.CrossRefPubMed Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11–6.CrossRefPubMed
6.
Zurück zum Zitat Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307:1383–93.CrossRefPubMedPubMedCentral Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307:1383–93.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Foxtrot Collaborative G. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13:1152–60.CrossRef Foxtrot Collaborative G. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13:1152–60.CrossRef
8.
Zurück zum Zitat Jakobsen A, Andersen F, Fischer A, Jensen LH, Jørgensen JC, Larsen O, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol. 2015;29:1–7. Jakobsen A, Andersen F, Fischer A, Jensen LH, Jørgensen JC, Larsen O, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol. 2015;29:1–7.
9.
Zurück zum Zitat Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMed Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMed
10.
Zurück zum Zitat Hendren S, Birkmeyer JD, Yin H, Banerjee M, Sonnenday C, Morris AM. Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer. Dis Colon Rectum. 2010;53:1587–93.CrossRefPubMed Hendren S, Birkmeyer JD, Yin H, Banerjee M, Sonnenday C, Morris AM. Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer. Dis Colon Rectum. 2010;53:1587–93.CrossRefPubMed
11.
Zurück zum Zitat Arredondo J, Pastor C, Baixauli J, Rodríguez J, González I, Vigil C, et al. Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer. Colorectal Dis. 2013;15:552–7.CrossRefPubMed Arredondo J, Pastor C, Baixauli J, Rodríguez J, González I, Vigil C, et al. Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer. Colorectal Dis. 2013;15:552–7.CrossRefPubMed
12.
Zurück zum Zitat Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82.CrossRefPubMed Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82.CrossRefPubMed
13.
Zurück zum Zitat Shia J, Guillem JG, Moore HG, Tickoo SK, Qin J, Ruo L, et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol. 2004;28:215–23.CrossRefPubMed Shia J, Guillem JG, Moore HG, Tickoo SK, Qin J, Ruo L, et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol. 2004;28:215–23.CrossRefPubMed
14.
Zurück zum Zitat Iachetta F, Reggiani Bonetti L, Marcheselli L, Di Gregorio C, Crilli C, Messinese S, et al. Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: a population-based study. Acta Oncol. 2013;52:1682–90.CrossRefPubMed Iachetta F, Reggiani Bonetti L, Marcheselli L, Di Gregorio C, Crilli C, Messinese S, et al. Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: a population-based study. Acta Oncol. 2013;52:1682–90.CrossRefPubMed
15.
Zurück zum Zitat Arredondo J, Martínez P, Baixauli J, Pastor C, Rodríguez J, Pardo F, et al. Analysis of surgical complications of primary tumor resection after neoadjuvant treatment in stage IV colon cancer. J Gastrointest Oncol. 2014;5:148–53.PubMedPubMedCentral Arredondo J, Martínez P, Baixauli J, Pastor C, Rodríguez J, Pardo F, et al. Analysis of surgical complications of primary tumor resection after neoadjuvant treatment in stage IV colon cancer. J Gastrointest Oncol. 2014;5:148–53.PubMedPubMedCentral
16.
Zurück zum Zitat Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRefPubMed Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRefPubMed
17.
Zurück zum Zitat Cienfuegos JA, Rotellar F, Baixauli J, Beorlegui C, Sola JJ, Arbea L, et al. Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery. Ann Surg Oncol. 2015;22:916–23.CrossRefPubMed Cienfuegos JA, Rotellar F, Baixauli J, Beorlegui C, Sola JJ, Arbea L, et al. Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery. Ann Surg Oncol. 2015;22:916–23.CrossRefPubMed
18.
Zurück zum Zitat Dighe S, Swift I, Magill L, Handley K, Gray R, Quirke P, et al. Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. Colorectal Dis. 2012;14:438–44.CrossRefPubMed Dighe S, Swift I, Magill L, Handley K, Gray R, Quirke P, et al. Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. Colorectal Dis. 2012;14:438–44.CrossRefPubMed
19.
Zurück zum Zitat Smith NJ, Bees N, Barbachano Y, Norman AR, Swift RI, Brown G, et al. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials. Br J Cancer. 2007;96:1030–6.CrossRefPubMedPubMedCentral Smith NJ, Bees N, Barbachano Y, Norman AR, Swift RI, Brown G, et al. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials. Br J Cancer. 2007;96:1030–6.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Arredondo J, González I, Baixauli J, et al. Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy. J Gastrointest Oncol. 2014;5:104–11.PubMedPubMedCentral Arredondo J, González I, Baixauli J, et al. Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy. J Gastrointest Oncol. 2014;5:104–11.PubMedPubMedCentral
21.
Zurück zum Zitat Huh JW, Jeong YY, Kim HR, Kim YJ. Prognostic value of preoperative radiological staging assessed by computed tomography in patients with nonmetastatic colon cancer. Ann Oncol. 2012;23:1198–206.CrossRefPubMed Huh JW, Jeong YY, Kim HR, Kim YJ. Prognostic value of preoperative radiological staging assessed by computed tomography in patients with nonmetastatic colon cancer. Ann Oncol. 2012;23:1198–206.CrossRefPubMed
22.
Zurück zum Zitat Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, El Mansy H, Garcia C, et al. Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer. 2013;13:190.CrossRefPubMedPubMedCentral Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, El Mansy H, Garcia C, et al. Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer. 2013;13:190.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Cervantes A. Preoperative chemotherapy for colon cancer is getting closer. Lancet Oncol. 2012;13:1073–4.CrossRefPubMed Cervantes A. Preoperative chemotherapy for colon cancer is getting closer. Lancet Oncol. 2012;13:1073–4.CrossRefPubMed
24.
Zurück zum Zitat Zhou Z, Nimeiri HS, Benson AB 3rd. Preoperative chemotherapy for locally advanced resectable colon cancer—a new treatment paradigm in colon cancer? Ann Transl Med. 2013;1:11.PubMedPubMedCentral Zhou Z, Nimeiri HS, Benson AB 3rd. Preoperative chemotherapy for locally advanced resectable colon cancer—a new treatment paradigm in colon cancer? Ann Transl Med. 2013;1:11.PubMedPubMedCentral
25.
Zurück zum Zitat Mayor S. Chemotherapy before surgery for colon cancer may improve survival, study shows. BMJ. 2012;345:e7487.CrossRefPubMed Mayor S. Chemotherapy before surgery for colon cancer may improve survival, study shows. BMJ. 2012;345:e7487.CrossRefPubMed
Metadaten
Titel
Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery
verfasst von
J. Arredondo
J. Baixauli
C. Pastor
A. Chopitea
J. J. Sola
I. González
J. A-Cienfuegos
P. Martínez
J. Rodriguez
J. L. Hernández-Lizoain
Publikationsdatum
05.08.2016
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 3/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1539-4

Weitere Artikel der Ausgabe 3/2017

Clinical and Translational Oncology 3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.